Historical gild News Stories
Gilead Surges: Q4 Beat, Dividend Hike & Upgrades!!
Gilead (GILD) climbed to fresh highs after a February earnings beat, a dividend increase and multiple analyst price-target raises. Strong HIV franchise results—led by Biktarvy and the growing Yeztugo launch—plus durable oncology sales powered the move, while cell-therapy softness and cautious 2026 guidance temper near-term expectations.
Gilead Surges on Trodelvy+Keytruda NEJM Win Shares
Gilead shares climbed to fresh 52-week highs after the New England Journal of Medicine published Phase III ASCENT‑04/KEYNOTE‑D19 results showing strong efficacy for Trodelvy (sacituzumab govitecan) combined with Merck’s Keytruda in PD-L1+ metastatic triple-negative breast cancer. The NEJM publication (Jan 21) and subsequent investor reaction produced consecutive trading-day gains (Feb 4–5, 2026), elevated volume and roughly a 20.8% monthly uptick. This article breaks down the concrete clinical and market catalysts driving GILD’s momentum and the near-term implications for investors.
Gilead Gains: Q4, Analyst Ups, New Antivirals Rise
Gilead (GILD) pushed to fresh 52-week highs late January after a strong quarterly update, analyst upgrades and targeted pipeline additions — notably in HIV, oncology and new HSV antivirals. Recent momentum is driven by robust HIV sales, Trodelvy clinical progress and strategic licensing that broadens Gilead’s antiviral footprint.
Gilead Rally: Lenacapavir, Trodelvy, HSV Deal Now!
Gilead shares climbed to fresh 52-week highs after investor events and concrete pipeline progress. Key catalysts include regulatory momentum for lenacapavir (Yeztugo), promising oncology data for Trodelvy, a strategic HSV licensing deal, and sustained HIV franchise revenue.
Gilead's Yeztugo & HSV Deal Reshape GILD Value Now
Recent analyst upgrades, a strategic HSV licensing deal, and supportive clinical readouts at IDWeek/CROI have boosted Gilead's (GILD) growth narrative — key catalysts for near-term stock movement.
GILD Slides; Licensing Earnings Date Shape Outlook
Gilead shares declined this week as a sector rotation into energy pressured biotech names, while company-specific licensing and collaboration moves modestly bolstered its antiviral pipeline. With shares near $120.67, a forward P/E around 14.5 and a February earnings report ahead, investors must weigh macro headwinds against measured pipeline progress.
Gilead Gains: Lenacapavir, Trodelvy, Veklury Wins!
Gilead’s recent data releases and regulatory moves — new lenacapavir findings at IDWeek, Veklury REDPINE results, Trodelvy+Keytruda efficacy signal, and EU approval for seladelpar — reinforce multi-asset momentum. Strong HIV product sales and targeted oncology wins create clear near-term catalysts for GILD in the Nasdaq‑100.
GILD Rally: ARTISTRY-2 Boosts Long-Acting HIV Bets
Gilead’s ARTISTRY‑2 Phase III topline victory for a bictegravir‑lenacapavir single‑tablet regimen and upcoming presentations at IDWeek have created clear, near‑term catalysts for GILD. The data showing non‑inferiority to Biktarvy at Week 48, a clean safety profile, and ongoing lenacapavir development (Yeztugo) strengthen Gilead’s long‑acting HIV franchise and may influence regulatory filings and investor sentiment.
Gilead: New HIV Win, Arcus Setback Shakes Shares!!
This week Gilead scored a late‑stage HIV trial win with a bictegravir+lenacapavir tablet, while an Arcus anti‑TIGIT failure rattled oncology sentiment; Trodelvy sales and extended Biktarvy exclusivity underpin revenue stability.
Gilead Stock Slides Amid Biotech M&A Surge Q4 View
Gilead (GILD) traded lower this week amid elevated volume and a modest rebound midweek. While no company-specific clinical or commercial news surfaced, a broader surge in biotech M&A activity is providing sector tailwinds that could indirectly support Gilead’s shares. Investors should monitor upcoming catalysts and earnings for clearer direction.
Gilead Ships Lenacapavir to Africa; ARTISTRY Win!!
Gilead announced first shipments of twice‑yearly injectable lenacapavir (Yeztugo) to Eswatini and Zambia and reported a positive Phase 3 ARTISTRY‑1 readout for a bictegravir/lenacapavir single‑tablet regimen. These concrete clinical and commercial moves coincide with muted near‑term stock performance, while upcoming IDWeek presentations and recent CROI data keep the company’s HIV and antiviral pipeline in focus.
GILD Update: Lenacapavir Launch, ARTISTRY Win Now!
Gilead's recent week brought concrete clinical and commercial developments: lenacapavir shipments to Eswatini and Zambia, positive ARTISTRY‑1 Phase 3 topline results for a bictegravir–lenacapavir single‑tablet regimen, a setback in the ASCENT‑07 Trodelvy PFS endpoint with an early OS signal, and robust long‑term data for Livdelzi in PBC. These events are already influencing GILD's share activity and near‑term investor sentiment.
GILD Surge: Lenacapavir Wins, Biktarvy Patent Gain
Gilead's recent week brought concrete clinical and commercial catalysts: IDWeek presentations reinforcing lenacapavir's PrEP profile, EMPOWER data supporting Biktarvy switches, a strategic PEPFAR distribution deal, EU nods for lenacapavir, and solid Q3 2025 results that extended Biktarvy exclusivity—factors combining to strengthen GILD's near- and long-term outlook.
Gilead's Biktarvy, Lenacapavir Drive GILD Rally Q4
Recent clinical readouts — strong Biktarvy results in HIV/HBV coinfection, Breakthrough Therapy designation for lenacapavir combos, and positive ARTISTRY‑1 topline data — have produced concrete regulatory momentum and a near-term stock uptick for Gilead (GILD). This article breaks down the data, market reaction, and the near-term catalysts investors should track.
Gilead Readies Liver Data; Bulevirtide BLA Near FDA
Gilead will present long-term data for seladelpar (Livdelzi) and bulevirtide at The Liver Meeting 2025, while a bulevirtide BLA remains under FDA review. These developments could influence GILD sentiment by reinforcing Gilead’s liver-disease franchise and near-term regulatory catalysts.